{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"35","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Scan at 6 months\n\nComplete response: Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks\n\nPartial response: Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.\n\nProgressive disease: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.\n\nStable disease: Clinical status and MRI does not qualify for complete response, partial response or progression","dispersionType":"95% Confidence Interval","groups":[{"description":"IV Rituximab 750mg/m2 single infusion every week for up to 4 weeks.\n\nInduction: Rituximab (750mg/m2) Day 1, 8, 15 and 22 and Temozolomide \\[TMZ\\] (150mg/m2) days 1-7 and 15-21, followed by six cycles of consolidation TMZ 150-200mg/m2 x5/28days, followed by maintenance with methylprednisolone (1g IV every 28days) until progression\n\nrituximab: given IV days 1,8, 15 and 22\n\nmethylprednisolone: 2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)\n\ntemozolomide: Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles","id":"OG000","title":"IV Rituximab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months","title":"6-month Progression-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}